OmaliRel™
Brand Name: OmaliRel™
Composition: Omalizumab 150 ml, Recombinant humanized anti-IgE antibody
Product Description
Medical Info
OmaliRel™ 150 mg is an advanced targeted biologic therapy containing Omalizumab, a recombinant humanized monoclonal antibody designed as a potent anti-IgE treatment. Developed by Reliance Life Sciences, this subcutaneous injection is primarily indicated for managing moderate-to-severe persistent allergic asthma in patients whose symptoms remain uncontrolled despite standard therapies. It is also highly effective in treating chronic spontaneous urticaria (CSU) when antihistamines fail. By selectively binding to free immunoglobulin E (IgE) in the blood, OmaliRel™ prevents the inflammatory cascade that triggers allergic responses, offering significant therapeutic relief under specialist medical supervision.
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
